Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Healthcare utilisation of 282,080 individuals with long COVID over two years: a multiple matched control, longitudinal cohort analysis.
Mu Y, Dashtban A, Mizani MA, Tomlinson C, Mohamed M, Ashworth M, Mamas M, Priedon R, Petersen S, Kontopantelis E, Horstmanshof K, Pagel C, Hocaoğlu M, Khunti K, Williams R, Thygesen J, Lorgelly P, Gomes M, Heightman M, Banerjee A; CVD-COVID-UK/COVID-IMPACT Consortium. Mu Y, et al. Among authors: lorgelly p. J R Soc Med. 2024 Nov;117(11):369-381. doi: 10.1177/01410768241288345. Epub 2024 Nov 27. J R Soc Med. 2024. PMID: 39603265 Free PMC article.
How is Value Defined in Molecular Testing in Cancer? A Scoping Review.
Minhinnick A, Santos-Gonzalez F, Wilson M, Lorgelly P. Minhinnick A, et al. Among authors: lorgelly p. Appl Health Econ Health Policy. 2024 Jul 9. doi: 10.1007/s40258-024-00901-4. Online ahead of print. Appl Health Econ Health Policy. 2024. PMID: 38980555 Review.
Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.
Mortensen HR, Populaire P, Hoffmann L, Moeller DS, Appelt A, Nafteux P, Muijs CT, Grau C, Hawkins MA, Troost EGC, Defraene G, Canters R, Clarke CS, Weber DC, Korevaar EW, Haustermans K, Nordsmark M, Gebski V, Achiam MP, Markar SR, Radhakrishna G, Berbee M, Scartoni D, Orlandi E, Doyen J, Gregoire V, Crehange G, Langendijk J, Lorgelly P, Blommenstein HM, Byskov CS, Ehmsen ML, Jensen MF, Freixas GV, Bütof R; PROTECT consortium. Mortensen HR, et al. Among authors: lorgelly p. Radiother Oncol. 2024 Jan;190:109980. doi: 10.1016/j.radonc.2023.109980. Epub 2023 Nov 5. Radiother Oncol. 2024. PMID: 37935284 Free article. No abstract available.
Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol.
Asif A, Nathan A, Ng A, Khetrapal P, Chan VW, Giganti F, Allen C, Freeman A, Punwani S, Lorgelly P, Clarke CS, Brew-Graves C, Muirhead N, Emberton M, Agarwal R, Takwoingi Y, Deeks JJ, Moore CM, Kasivisvanathan V; PRIME Trial Group. Asif A, et al. Among authors: lorgelly p. BMJ Open. 2023 Apr 5;13(4):e070280. doi: 10.1136/bmjopen-2022-070280. BMJ Open. 2023. PMID: 37019486 Free PMC article.
STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol.
Forshaw D, Wall EC, Prescott G, Dehbi HM, Green A, Attree E, Hismeh L, Strain WD, Crooks MG, Watkins C, Robson C, Banerjee R, Lorgelly P, Heightman M, Banerjee A; STIMULATE-ICP trial team. Forshaw D, et al. Among authors: lorgelly p. PLoS One. 2023 Feb 15;18(2):e0272472. doi: 10.1371/journal.pone.0272472. eCollection 2023. PLoS One. 2023. PMID: 36791116 Free PMC article.
111 results